UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 22

of '进展期(晚期)或转移性肾透明细胞癌的抗血管生成和分子靶向治疗'

22
TI
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
AU
Choueiri TK, Escudier B, Powles T, et al
SO
Lancet Oncol. 2016;
 
AD